DIA Biosimilars 2013

Marina Biotech

Arcturus Therapeutics acquires UNA patent estate from Marina Biotech

Friday, August 16, 2013 12:10 PM

Arcturus Therapeutics, which focuses on RNA interference (RNAi) technologies for the treatment of disease, has acquired the patented portfolio of Unlocked Nucleobase Analog (UNA) intellectual property from Marina Biotech. Financial terms of the UNA agreement were not disclosed.

More... »

Cenduit: Now with Patient Reminders

Marina Biotech reduces board size, seeks funding

Wednesday, August 22, 2012 01:35 PM

Marina Biotech, a nucleic acid-based drug discovery and development company, continues to seek adequate funding to implement its business plan.

More... »

CRF Health – eCOA Forum

Marina Biotech lays off 90% of staff

Friday, June 1, 2012 10:20 AM

Marina Biotech, a nucleic acid-based drug discovery and development company based in Bothell, Wash., announced that it does not currently have adequate funding to continue implementing its business plan.

More... »

Marina Biotech to close Cambridge site

Thursday, February 16, 2012 06:33 AM

Marina Biotech, a nucleic acid-based drug discovery and development company, will be closing its Cambridge, Mass., site and consolidating all R&D efforts at its headquarters in Bothell, Wash.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs